The Neonatal and Paediatric Pharmacokinetics of Antimicrobials study (NAPPA): investigating amoxicillin, benzylpenicillin, flucloxacillin and piperacillin pharmacokinetics from birth to adolescence

Charlotte I. S. Barker [1,2,3,4]*, Karin Kipper [1,5,6,7], Dagan O. Lonsdale [1,2], Kirstie Wright[1], Georgina Thompson[1], Min Kim[1,3], Mark A. Turner [8], Atholl Johnston [5,9], Mike Sharland [1,2] and Joseph F. Standing [1,3,10]†on behalf of the NAPPA Study Consortium

[1]Centre for Neonatal and Paediatric Infection, Level 2 Jenner Wing, Institute for Infection and Immunity, St George's, University of London SW17 0RE, London, UK; [2]Paediatric Infectious Diseases Department, St George's University Hospitals NHS Foundation Trust, London, UK; [3]Infection, Immunity and Inflammation Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK; [4]Department of Medical & Molecular Genetics, King's College London, London, UK; [5]Analytical Services International, St George's, University of London, London, UK; [6]Analytical Chemistry Department, Epilepsy Society, Chesham Lane, Chalfont St Peter, Buckinghamshire, UK; [7]Institute of Chemistry, University of Tartu, Tartu, Estonia; [8]Department of Women's and Children's Health, University of Liverpool, Liverpool Health Partners, Liverpool, UK; [9]Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London, UK; [10]Pharmacy Department, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK

*Corresponding author. E-mail: cisbark4444@doctors.org.uk
†Members of the NAPPA Study Consortium are listed in the Acknowledgements section.

Background: Pharmacokinetic (PK) data underlying paediatric penicillin dosing remain limited, especially in critical care.

Objectives: The primary objective of the Neonatal and Paediatric Pharmacokinetics of Antimicrobials study (NAPPA) was to characterize PK profiles of commonly used penicillins using data obtained during routine care, to further understanding of PK variability and inform future evidence-based dosing.

Methods: NAPPA was a multicentre study of amoxicillin, co-amoxiclav, benzylpenicillin, flucloxacillin and piperacillin/tazobactam. Patients were recruited with informed consent. Antibiotic dosing followed standard of care. PK samples were obtained opportunistically or at optimal times, frozen and analysed using UPLC with tandem MS. Pharmacometric analysis was undertaken using NONMEM software (v7.3). Model-based simulations ($n = 10\,000$) tested PTA with British National Formulary for Children (BNFC) and WHO dosing. The study had ethical approval.

Results: For the combined IV PK model, 963 PK samples from 370 participants were analysed simultaneously incorporating amoxicillin, benzylpenicillin, flucloxacillin and piperacillin data. BNFC high-dose regimen simulations gave these PTA results (median $fT_{>MIC}$ at breakpoints of specified pathogens): amoxicillin 100% (*Streptococcus pneumoniae*); benzylpenicillin 100% (Group B *Streptococcus*); flucloxacillin 48% (MSSA); and piperacillin 100% (*Pseudomonas aeruginosa*). Oral population PK models for flucloxacillin and amoxicillin enabled estimation of first-order absorption rate constants (1.16 h^{-1} and 1.3 h^{-1}) and bioavailability terms (62.7% and 58.7%, respectively).

Conclusions: NAPPA represents, to our knowledge, the largest prospective combined paediatric penicillin PK study undertaken to date, and the first paediatric flucloxacillin oral PK model. The PTA results provide evidence supportive of BNFC high-dose IV regimens for amoxicillin, benzylpenicillin and piperacillin.

Introduction

Over 80 years since the first documented use of penicillin therapy in children,[1] β-lactam antibiotics remain the most widely used class of medications in paediatrics.[2] Furthermore, despite widespread antibiotic availability and the success of paediatric vaccination programmes, infectious diseases are still a leading cause of global childhood morbidity and mortality.[3,4] The pharmacokinetic/pharmacodynamic (PKPD) data underlying paediatric β-lactam dosing regimens are limited, particularly in neonates,[5] and standard dosing regimens in different formularies and countries vary enormously.[6] Consequently, PKPD studies within these vulnerable populations, particularly those in ICU, are needed in order to support the development of updated evidence-based dosing regimens.[7]

The target PKPD index for penicillin therapy is the percentage of time within the dosing interval that the free (unbound) concentration of the penicillin antibiotic (as quantified in the blood) remains above the MIC, commonly abbreviated to %$fT_{>MIC}$.[7] The traditional PKPD target for penicillin therapy in humans aimed to achieve at least 40% $fT_{>MIC}$; this target was originally obtained from *in vitro* and *in vivo* studies,[8–10] where it was determined to be the best PKPD predictor of both bacterial killing and microbiological response.[11] However, in recent years, this target has sometimes been increased to 70% $fT_{>MIC}$ (or up to 100% $fT_{>MIC}$ or 100% >4× MIC) in the context of critical illness.[12–15] Given that many neonates receiving in-hospital antimicrobial therapy are critically ill or at risk of critical illness given their functional immunocompromise (relating to immune system immaturity), 70%–100% $fT_{>MIC}$ is sometimes advocated for neonates. These theoretical reasons for increasing the target %$fT_{>MIC}$ have led to extensive research into prolonged or continuous β-lactam infusions in critical care, the majority of which has focused on adult patients.[16–18]

Here we report the results from the Neonatal and Paediatric Pharmacokinetics of Antimicrobials study (NAPPA). NAPPA was a post-marketing prospective population pharmacokinetic study that aimed to use data acquired from sparse sampling strategies to develop a paediatric population pharmacokinetic model of five penicillins [amoxicillin, co-amoxiclav (amoxicillin/clavulanate), ampicillin, benzylpenicillin, flucloxacillin and piperacillin/tazobactam], which are collectively referred to as the 'NAPPA penicillins' in this manuscript. The objective was to characterize the PK profiles of these penicillins when used in hospital within routine clinical care, to further understanding of pharmacokinetic variability, and help inform future paediatric evidence-based dosing regimens.

Methods

Clinical study

Patients were recruited at nine NHS hospital sites from November 2013 until February 2016. Potentially eligible patients, identified by screening of participating ICUs and wards, were invited to enrol, and provided with study information. Written informed consent was obtained from each participant's parent/guardian. Assent was sought from patients aged over 6 years. The inclusion criteria were: child aged under 16 years receiving one of the NAPPA penicillins (either IV or orally) and requiring IV access or blood test(s) as part of routine care. The exclusion criteria were: patient deemed unlikely to survive for 48 h after recruitment, pregnancy,

known β-lactam or β-lactamase inhibitor (BLI) allergy/hypersensitivity, or care requiring renal replacement therapy, extracorporeal membrane oxygenation or cardiopulmonary bypass.

Clinical data were collected from participants' medical records, including demographic information, weight, medical history, level of care [general, High Dependency Unit (HDU), Neonatal/Paediatric ICU], results of haematological, biochemical and microbiological investigations, antibiotic dosing regimen details and concomitant medications. Data were recorded on standardized case report forms. Central data processing used the REDCap electronic data capture tool.[19]

Study antibiotics were prescribed by the attending physician according to clinical need, at the usual dose, following local guidelines and the British National Formulary for Children (BNFC)[20] (Table S1, available as Supplementary data at *JAC* Online) by the clinically appropriate route of administration. All participants had the usual blood test(s) required for routine care. In addition, at the time of other blood sampling where possible, an extra 0.5 mL aliquot of blood was obtained opportunistically. If intravascular access was *in situ* for clinical reasons, additional PK samples could also be taken at recommended times (Table S2), derived from the optimal design strategy, as previously described.[21] Blood samples, from an indwelling vascular catheter, venepuncture or heel-prick, were collected into EDTA-containing tubes, centrifuged, and the plasma stored at −70°C to −80°C before transfer for retrospective, batched laboratory analysis. The maximum number of study-specific samples per enrolment was eight.

The London Dulwich Research Ethics Committee approved the protocol (reference 13/LO/0907). The study was registered with EudraCT (EudraCT 2013-002366-40) and ClinicalTrials.gov (NCT01975493).

Analyte quantification

Antibiotic concentrations were measured in the Analytical Services International Ltd laboratory using UPLC with tandem MS. The method development and validation details were previously published.[22]

PK analysis

Population PK modelling was undertaken using non-linear mixed-effects modelling software NONMEM® (version 7.3, ICON plc). A combined population-PK model was fitted simultaneously to the measured drug concentration–time data following IV administration for all study penicillins. The total (bound and unbound) concentration data were analysed to derive a base structural disposition model. The first-order conditional estimation method with interaction (FOCE-I) was utilized. First-order (linear) elimination kinetics were assumed. Standard compartmental linear models were tested (up to a maximum of two compartments). The M5 method was used to handle data below the limit of quantification (BLQ), setting BLQ data points to BLQ/2 for analysis.[23] Interindividual variability was tested for all parameters (assuming a log-normal distribution, as all envisaged parameters were continuous). The residual variability model first tested was a combined proportional and additive residual error model. No other error models were tested as this gave a suitable fit. Since the data were sparse no interoccasion variability was included. R studio (version 1.1.414) with R software (version 3.3.3) was used for data management.

Allometric weight scaling was included *a priori* with fixed allometric exponents of 1.0 and 0.75 for volume and clearance terms, respectively. For clearance parameters, the allometric weight scaling was combined with a Hill model using postmenstrual age (PMA) in weeks to describe the maturation function (as derived by Rhodin *et al.*[24] in 2009 given expected clearance is principally by glomerular filtration, particularly during the neonatal period and infancy):

$$CL = CL_T \cdot \left(\frac{WT}{70}\right)^{0.75} \cdot \frac{PMA^{Hill}}{PMA_{50}^{Hill} + PMA^{Hill}} \tag{1}$$

Table 1. Dosing regimens used for the model-based simulations

Penicillin	Age groups	BNFC high-dose regimen	BNFC low-dose regimen	WHO regimen
Amoxicillin	PNA < 7 days	60 mg/kg q12h	30 mg/kg q12h	30 mg/kg q8h
	PNA ≥ 7 days	60 mg/kg (max 1 g) q8h	30 mg/kg (max 500 mg) q8h	30 mg/kg (max 500 mg) q8h
Benzylpenicillin	PNA < 7 days	50 mg/kg q12h	25 mg/kg q8h	30 mg/kg q8h
	PNA 7–27 days	50 mg/kg q8h	25 mg/kg q8h	30 mg/kg q8h
	PNA ≥ 28 days	50 mg/kg (max 2.4 g) q4h	25 mg/kg (max 2.4 g) q6h	N/A
Flucloxacillin	PNA < 7 days	100 mg/kg q12h	50 mg/kg q12h	50 mg/kg q12h
	PNA 7–20 days	100 mg/kg q8h	50 mg/kg q8h	
	PNA ≥ 21–27 days	100 mg/kg (max 2 g) q6h	50 mg/kg (max 2 g) q6h	
	PNA ≥ 28 days			25 mg/kg (max 2 g) q4h
Piperacillin	PNA < 28 days	90 mg/kg q8h	N/A	100 mg/kg q8h
	PNA ≥ 28 days	90 mg/kg (max. 4.5 g) q6h	N/A	100 mg/kg (max 4.5 g) q8h

Max, maximum. Expanded details of the BNFC dosing recommendations for different clinical indications are included in the Supplementary data.

where PMA_{50} is the PMA in weeks at which drug clearance reaches half the mature (adult) value. To further account for the changes in clearance during the early days of life, a covariate function based on postnatal age (PNA), as previously described,[25] was also tested:

$$PNA_{function} = \theta_M + (1 - \theta_M) \times (1 - e^{-PNA_i\,\theta_N}) \quad (2)$$

Serum creatinine (SeCr) was tested as a covariate on clearance, using a power model adjusted for the ratio to the mean age-adjusted creatinine, calculated using the Ceriotti formula:[26]

$$SeCr(mmol/L) = -2.37330 - 12.91367^*log(age) + 23.93581^*(age)^{0.5}$$
$$(3)$$

The output of this function reflects the expected fall in creatinine after birth (which is initially high as early measurements reflect maternal creatinine), followed by a steady rise with increasing age.

Further covariate analysis was not undertaken for the combined IV model as earlier covariate testing on the population PK data from the individual NAPPA penicillins had not identified any additional significant covariates (data not shown). Additional details are included in the Supplementary information.

Model evaluation and qualification procedures

Model selection was based on comparison of the objective function value (OFV) between competing models, in addition to the standard errors of parameter estimates, goodness-of-fit (GOF) plots and scientific plausibility. To aid model selection, simulation properties were tested with visual predictive checks (VPCs), generated using PsN software (version 4.7.0). A non-parametric bootstrap (with 1000 replicates) was used to assess the precision of final parameter estimates.

PTA evaluation

Model-based simulations, based on the final combined IV PK model, were used to evaluate the PTA with BNFC and WHO dosing regimens (Table 1) administered as an IV bolus.[20,27] The simulated patient population (n = 10 000) was randomly generated using the study participants' baseline demographics. The fraction of time spent above the MIC ($fT_{>MIC}$) over the first 24 h of therapy was the primary PD endpoint. Fixed protein binding was assumed, based on literature values (Table 2).[28–31] The EUCAST clinical breakpoints used are shown in Table 3.[32,33]

Table 2. Published protein binding percentages for the NAPPA penicillins

Penicillin	% Protein binding reported
Amoxicillin[28]	18
Benzylpenicillin[29]	60
Flucloxacillin[30]	95
Piperacillin[31]	30

Table 3. MIC cut-offs used for plots (mg/L)

Antibiotic	MIC S cut-off	MIC R cut-off
Amoxicillin	2	8
Benzylpenicillin	0.25	2
Flucloxacillin	—	2
Piperacillin	8	16

These cut-off values are based on EUCAST PKPD (non-species-related) breakpoints, apart from flucloxacillin where the cut-off of 2 mg/L for MSSA is used (inferred from the MSSA MIC for oxacillin, since EUCAST and CLSI do not publish MSSA MICs or clinical breakpoints for flucloxacillin).[32,33]

Analysis of oral amoxicillin and flucloxacillin PK data

The oral PK data for amoxicillin and flucloxacillin were analysed separately, together with the IV PK data from each drug, respectively; the parameters estimated from the combined IV PK model were fixed, and the absorption rate constant (k_a) and bioavailability term, F, were then estimated.

Results

Across all the penicillins combined, 428 patients were enrolled in the NAPPA study. For the combined IV PK model incorporating

Table 4. Demographic characteristics of each study population for the combined IV model

Demographic characteristics	Co-amoxiclav and amoxicillin ($n=174$)	Benzylpenicillin ($n=64$)	Flucloxacillin ($n=72$)	Piperacillin ($n=70$)
Weight (kg)	3.76 (0.58–70)	2.83 (0.57–64.3)	3.1 (0.585–67)	10.9 (0.6–85)
PNA (weeks)	7.21 (0.1–815.9)	0.3 (0.1–685.1)	6.714 (0.143–818.6)	90.4 (0.7–795)
Gestational age at birth (weeks)	38.6 (22.86–41.86)	37 (24–42.29)	37 (23–41.43)	40 (23–40)
PMA (weeks)	41.9 (23.6–855.9)	37.5 (24.1–725.1)	41.6 (24.7–858.6)	130 (24.7–835)
Female sex	72 (41.4)	28 (43.8)	37 (51.4)	32 (45.7)
ICU- or HDU-level care	157 (90.2)	56 (87.5)	57 (79.2)	63 (90)
Ventilation support or oxygen therapy	121 (69.5)	29 (45.3)	39 (54.2)	52 (74)
Renal impairment	7 (4.0)	2 (3.1)	0 (0)	2 (3)
Therapeutic hypothermia	9 (5.1)	2 (3.1)	0 (0)	0 (0)
Liver impairment	2 (1.1)	0 (0)	1 (1.4)	0 (0)
Baseline creatinine (µmol/L)	33 (2–102)	56 (14–105)	37 (11–81)	31 (6–95)
Urea (mmol/L)	3.3 (0.8–12.4)	3.1 (1.4–16.4)	3.5 (0.6–17)	3.4 (0.9–14.5)
Bilirubin (µmol/L)	26 (2–250)	118 (6–302)	16.5 (2–255)	6.5 (2–114)
AST (IU/L)	37 (12–4153)	37 (18–144)	27.5 (11–166)	25 (12–384)
ALT (IU/L)	19 (3–2212)	16 (5–191)	17 (5–131)	22 (5–342)
ALP (IU/L)	359 (47–2010)	249 (92–735)	320 (23–1196)	278 (2–1121)
Albumin (g/L)	28 (17–47)	30 (15–38)	29 (16–47)	27.5 (12–45)
Haematocrit	0.34 (0.21–0.66)	0.48 (0.25–0.74)	0.35 (0.25–0.64)	0.30 (0.21–0.49)
CRP (mg/L)	18.5 (0.1–281)	16.55 (0.2–172.3)	6.85 (1–146.4)	57 (0.4–388.7)
Median IV dose (mg/kg/dose)	25.2 (9.7–112)	25.4 (20.8–59.4)	25.1 (12.4–100)	80 (47–125)
Total sample number	409	147	185	222

Continuous data are presented as median (range) and categorical data are presented with the number of subjects (% of total). ALP, alkaline phosphatase; CRP, C-reactive protein. Only those study participants contributing PK samples are included.

Table 5. Indications for antibiotic treatment for study populations of the combined IV model

Indication for antibiotic therapy	Co-amoxiclav and amoxicillin ($n=174$)	Benzylpenicillin ($n=64$)	Flucloxacillin ($n=72$)	Piperacillin ($n=70$)
Suspected or proven sepsis (including bacteraemia), n (%)	81 (46.6)	49 (76.6)	34 (47.2)	18 (21.7)
Surgical prophylaxis, n (%)	38 (21.8)	0 (0)	11 (15.3)	4 (4.8)
LRTI (including CAP), n (%)	18 (10.3)	0 (0)	5 (6.9)	20 (24.1)
Intra-abdominal infection (including NEC), n (%)	12 (6.9)	0 (0)	0 (0)	4 (4.8)
Medical prophylaxis, n (%)	9 (5.2)	12 (18.8)	1 (1.4)	7 (8.4)
Meningitis, n (%)	7 (4)	1 (1.6)	1 (1.4)	0 (0)
Urinary tract infection, n (%)	3 (1.7)	0 (0)	0 (0)	0 (0)
Hospital-acquired pneumonia (HAP), n (%)	2 (1.1)	2 (3.1)	0 (0)	4 (4.8)
Ventilator-associated HAP, n (%)	0 (0)	1 (1.6)	0 (0)	4 (4.8)
Aspiration pneumonia, n (%)	0 (0)	0 (0)	0 (0)	2 (2.4)
Pharyngitis, n (%)	1 (0.6)	1 (1.6)	0 (0)	1 (1.2)
Skin or soft tissue infection, n (%)	1 (0.6)	3 (4.7)	19 (26.4)	0 (0)
Septic arthritis or osteomyelitis, n (%)	1 (0.6)	2 (3.1)	4 (5.6)	0 (0)
Febrile neutropenia or neutropenic sepsis, n (%)	1 (0.6)	0 (0)	1 (1.4)	6 (7.2)
Endocarditis, n (%)	0 (0)	1 (1.6)	2 (2.8)	0 (0)
Congenital pneumonia, n (%)	0 (0)	2 (3.1)	0 (0)	0 (0)
Other, n (%)	15 (8.6)	2 (3.1)	2 (2.8)	13 (15.7)

LRTI, lower respiratory tract infection; CAP, community-acquired pneumonia, NEC, necrotizing enterocolitis. Note some patients had more than one indication for antibiotic therapy recorded, hence the total number of indications is greater than the total number of subjects. Note the total number of patients across all penicillin groups is higher than the overall total $n=370$ because 10 participants contributed samples for two different penicillins.

Table 6. NAPPA combined IV model: final parameter estimates and bootstrap results

Drug:	Amoxicillin			Benzylpenicillin			Flucloxacillin			Piperacillin		
Parameter	Point estimate (RSE)	S (%)	BS (95% CI)	Point estimate (RSE)	S (%)	BS (95% CI)	Point estimate (RSE)	S (%)	BS (95% CI)	Point estimate (RSE)	S (%)	BS (95% CI)
TVCL	16.4 (7.1)	—	16.5 (14.0–18.8)	7.17 (13)	—	7.25 (5.29–9.61)	14.6 (8.4)	—	14.7 (12.5–17.5)	8.59 (7.9)	—	8.57 (7.44–10.1)
TVV	46.2 (4.8)	—	46.2 (42.4–51.0)	11.8 (10.5)	—	11.8 (9.86–14.6)	23.3 (8.5)	—	23.7 (20.3–28.3)	18.6 (8.7)	—	18.6 (15.4–22.1)
Var IIV (1)	0.167 (26.4)	39.2	0.152 (0.085–0.278)	0.249 (25.6)	60.6	0.238 (0.119–0.373)	0.237 (19.6)	58.8	0.225 (0.136–0.321)	0.225 (32.2)	59	0.220 (0.084–0.374)
Var IIV (2)	0.045 (57.3)	70.3	0.043 (0.005–0.099)	—		—	0.024 (137.4)	85.6	0.033 (0.0005–0.178)	—		—
Var prop RE	0.135 (16.4)	16.6	0.134 (0.092–0.184)	0.241 (15.5)	12.3	0.234 (0.168–0.315)	0.179 (15.7)	13.5	0.170 (0.123–0.229)	0.212 (15.4)	8.8	0.209 (0.153–0.280)
Var add RE	—	—	—	0.012 (163.1)	12.3	0.011 (0.001–0.836)	—		—	—		—

Parameter	Amoxicillin Point estimate (RSE, %)	Flucloxacillin Point estimate	BS (95% CI)
T50	42.6 (9.1)	43.5	35.6–50.7
Hill	2.68 (6.3)	2.80	2.16–3.34
M	0.516 (13.1)	0.486	0.340–0.659
N	0.020 (50.5)	0.022	0.011–0.176
Creat on CL	−0.302 (27.7)	−0.301	−0.471 to −0.136

S shrinkage (%); BS, bootstrap; TVCL, typical value of clearance in L/h/70 kg; TVV, typical value of volume in L/70 kg; T50, maturation half time (PMA in weeks); Hill, Hill coefficient; M, fraction of CL on day of birth; N, rate of maturation post birth; Creat on CL, creatinine covariate on clearance; Var, variance; IIV (1), variance of IIV on CL; IIV (2), variance of IIV on V; prop RE, proportional component of the residual error; add RE, additive component of the residual error. All bootstrap results are presented as median (2.5th–97.5th percentiles).

Figure 1. GOF plot for combined IV model, stratified by drug: observed concentrations plotted against population predictions for amoxicillin, benzyl-penicillin, flucloxacillin and piperacillin. This figure appears in colour in the online version of *JAC* and in black and white in the print version of *JAC*.


**Figure 2.** GOF plots for combined IV model, stratified by drug: observed concentrations plotted against individual predictions for amoxicillin, benzyl-penicillin, flucloxacillin and piperacillin. This figure appears in colour in the online version of *JAC* and in black and white in the print version of *JAC*.

**Figure 3.** GOF plots for combined IV model, stratified by drug: conditionally weighted residual errors plotted against time after dose (for 0–12 h following the IV dose) for amoxicillin, benzylpenicillin, flucloxacillin and piperacillin. Additional plot available in the Supplementary data. This figure appears in colour in the online version of *JAC* and in black and white in the print version of *JAC*.

Figure 4. VPC of combined IV model, showing observed concentrations (dots) in mg/L and prediction intervals (shaded areas) against time after dose in hours. The solid black line is the 50th percentile and the dashed lines are the 2.5[th] and 97.5[th] percentiles of the observed data, respectively. Each shaded area is a non-parametric 95% CI for the corresponding predicted concentrations. This figure appears in colour in the online version of *JAC* and in black and white in the print version of *JAC*.

Figure 5. Results of the model-based simulations testing the PTA for the BNFC high-dose regimens for all NAPPA penicillins. The panels each show the proportion of time above a range of MICs over the first 24 h of therapy for simulated patients ($n = 10\,000$). The dashed line represents the simulated median and the shaded area represents 95% of simulated patients' $fT_{>MIC}$. The solid vertical line indicates the EUCAST breakpoint MIC R (resistant). The dashed vertical line indicates the EUCAST MIC S (susceptible). Further simulation results are included in the Supplementary data. This figure appears in colour in the online version of *JAC* and in black and white in the print version of *JAC*.

amoxicillin (including participants receiving co-amoxiclav), benzylpenicillin, flucloxacillin and piperacillin PK data, a total of 963 evaluable PK samples from 370 participants were analysed simultaneously.

The baseline demographics of study participants and treatment indications are shown in Tables 4 and 5, respectively. Data points were excluded from model building if there were known protocol deviations, for example, if antibiotic dose

Table 7. Parameter estimates for separate oral flucloxacillin and amoxicillin PK models

Parameter	Parameter estimates	
	Flucloxacillin model	Amoxicillin model
TVCL	14.6 (fixed)	16.4 (fixed)
TVV	23.3 (fixed)	46.2 (fixed)
T50	42.6 (fixed)	42.6 (fixed)
Hill	2.68 (fixed)	2.68 (fixed)
M	0.516 (fixed)	0.516 (fixed)
N	0.0202 (fixed)	0.0202 (fixed)
Creat on CL	−0.302 (fixed)	−0.302 (fixed)
TVKA	1.16 (RSE 28.4%)	1.3 (RSE 52.4%)
F1	0.627 (RSE 8.1%)	0.587(RSE 15.3%)
Var IIV (1)	0.237 (fixed) (s: 8.1%)	0.167 (fixed) (s: 11.8%)
Var IIV (2)	0.024 (fixed) (s: 67.7%)	0.045 (fixed) (s: 57.3%)
Var prop RE	0.196 (RSE 14.5%) (s: 12.7%)	0.141(RSE 14.2%)(s: 16.3%)

TVCL, typical value of clearance in L/h/70 kg; TVV, typical value of volume in L/70 kg; TVQ, typical value of intercompartmental clearance in L/h/70 kg; TVV2, typical value of peripheral volume in L/70 kg; T50, maturation half time (PMA in weeks); Hill, Hill coefficient; M, fraction of CL on day of birth; N, rate of maturation post birth; Creat on CL, creatinine covariate on clearance; TVKA, typical value for the first-order absorption rate constant in h^{-1}; F1, bioavailability term; Var, variance; Var IIV (1), variance of IIV on CL; Var IIV (2), variance of IIV on V; s, shrinkage; prop RE, proportional residual error.

administration details were not recorded ($n = 3$). Two piperacillin data points were excluded where the measured concentration were greater than 1000 mg/L, since sample contamination was suspected, as concentrations this high have not previously been reported. The ampicillin data were excluded as only three participants were enrolled.

The concentration was BLQ in 19 samples (representing 2% of the total). A further two BLQ data points obtained from a single participant on benzylpenicillin were excluded as no quantifiable samples were obtained from this participant (and their inclusion prevented model minimization).

In the population PK analysis, inclusion of the PNA-driven covariate function (to reflect maturation of clearance after birth, independent of gestational age at birth) and the creatinine covariate function on clearance improved model fit over the base joint one-compartment model with *a priori* allometric weight scaling. The minimization and covariance step were successful. Table 6 summarizes the final parameter estimates, which were used for the PTA simulations. The GOF plots and VPCs are shown in Figures 1–4. Further GOF plots are included in the Supplementary data, together with the NONMEM code for the final model.

Model-based simulations
Figure 5 shows the results of the model-based simulations for each NAPPA penicillin, which demonstrates the %$fT_{>MIC}$ after the first 24 h of therapy using BNFC high-dose regimens (Table 1). Further simulation results, including those using WHO

dosing recommendations, are included for comparison in Figures S1–S6 and Tables S4–S6.[27]

Analysis of PK data from participants on oral amoxicillin and flucloxacillin
Sparse oral PK data were available from participants receiving oral flucloxacillin ($n = 9$) and amoxicillin (including co-amoxiclav) ($n = 7$). The demographics and indications are summarized in Tables S7 and S8. Table 7 shows the final parameter estimates. The GOF plots are shown in Figures S7–S14. The NONMEM code for these models is also included at the end of the Supplementary data.

Discussion

The NAPPA study represents, to our knowledge, the largest prospective combined penicillin PK study undertaken in children and neonates to date. The method demonstrated that recruitment to a paediatric clinical PK study is feasible within routine NHS care. Simultaneous modelling of the PK data from amoxicillin, benzylpenicillin, flucloxacillin and piperacillin together enabled use of a shared maturation function, which was thus informed by the combined data from these four different penicillins including neonatal, paediatric, and adolescent participants. This approach can help us to better understand that maturational component of developmental PK, capturing the physiological and pharmacological changes that evolve from birth to adulthood. However, it is important to note that joint PK modelling approaches combining data from different drugs should only be used for drugs that share similar clearance mechanisms.

Interpreting paediatric population PK parameter estimates necessitates comparison with the pre-existing literature, and the summaries of product characteristics (SPCs). Tables S9–S12 summarize comparisons of our results with previously published paediatric population PK studies. We adopted a standardized approach to scaling clearance, employing a standardized base model parametrization using allometric weight$^{0.75}$ and a sigmoidal maturation function, in order to facilitate model comparison and future extrapolation.[34,35] However, few previous studies adopted this method, and the parameterization of previous paediatric models varied significantly, making direct comparison difficult.[5]

Nevertheless, it remains necessary to explore potential explanations for differences between our results and previously published PK parameter estimates. We focused on comparing the NAPPA study estimates of clearance and volume of distribution (V_d) with those reported in the ABDose study, presented in Table S13.[36] The ABDose study recruited ICU patients of all ages. The majority of NAPPA participants were receiving ICU/HDU care, and the methods and standard operating procedures were consistent between the studies.

The estimate of clearance was very similar between NAPPA and ABDose for amoxicillin, whereas the NAPPA results were lower for piperacillin, and—much more markedly so—for benzylpenicillin. In contrast, the NAPPA estimate of flucloxacillin clearance was almost 2-fold higher. Depending on the study population for each drug under comparison, distinct factors are likely responsible for these different results. For example, the

NAPPA benzylpenicillin study population was principally neonates (median PNA 2 days), when a lower clearance is expected in relation to the participants' age and renal maturation stage. For flucloxacillin, the majority of ABDose participants were critically ill adults [52/59 PK samples (88%)], in whom a combination of age-related decline in renal function, and acute kidney injury (AKI) will have contributed to the lower clearance. Where one study population has an apparently increased clearance estimate, another probable contributing factor in ICU settings is augmented renal clearance (ARC).[37,38] These differences demonstrate that, even with the use of standardized scaling, the study population clinical context and demographics will contribute to different PK parameter estimates for clearance. Similarly, the SPC-reported clearance values for amoxicillin and piperacillin were higher than parameter estimates from both studies, reflecting their estimation from studies in healthy adult volunteers.

With respect to the apparent V_d values, the estimate was higher for ABDose for benzylpenicillin, similar for piperacillin, and higher for NAPPA for flucloxacillin and—much more strikingly so (61% higher)—for amoxicillin. Where elevated V_d estimates are identified, this is also likely secondary to several factors, including (in neonates) an increased fraction of unbound drug and relatively increased total body water,[39,40] and hypoalbuminaemia within the critically ill patient population.[41,42] V_d can also increase during sepsis, and secondary to pathophysiological changes (increased capillary permeability, interstitial oedema and altered protein binding), and iatrogenic factors.[43]

PTA and MIC selection

The PTA simulations (Figure 5) for BNFC high-dose regimens demonstrate mixed performances for these four penicillins. Combining the results for all age groups, and focusing specifically on the EUCAST non-species-related PKPD breakpoints (Table 3), the benzylpenicillin results are reassuring, with a median of 100% $fT_{>MIC}$ in the first 24 h. The BNFC low-dose regimen PTAs (Figure S2) are supportive of the NICE treatment guidelines for early-onset neonatal sepsis. Similarly, the piperacillin results are reassuring, with a median of 100% $fT_{>MIC}$ in the first 24 h. For amoxicillin, the median across all age groups was 79% $fT_{>MIC}$. The worst PTA results were for flucloxacillin, with a median of 48% $fT_{>MIC}$ across all age groups. This is largely a consequence of the assumption of 95% protein binding, discussed further below.

For PTA evaluation, MIC selection poses various challenges. Firstly, antibiotics prescribed for children are usually started empirically, in the absence of microbiological evidence.[44] A broad-spectrum therapeutic beginning is followed by de-escalation to narrow therapy agents when possible.[45] There are, however, some clinical contexts where selection of a lower MIC may be acceptable. For example, the use of the non-species-related breakpoint for benzylpenicillin will negatively influence the PTA interpretation, which improves if focusing instead on the MIC of 0.12 mg/L for Group B *Streptococcus*, which is most relevant for neonates. Consideration of different MICs should be determined by the clinical scenario. For example, the amoxicillin breakpoint for *Streptococcus pneumoniae*, a leading cause of sepsis in children, is 1.0 mg/L, whereas we have specified the median PTA above based on the EUCAST non-species-related PKPD breakpoints of 8.0 mg/L. For detailed consideration of the suitability of specific pathogen–penicillin combinations, the Supplementary data includes a tabular version of the PTA results for all simulated age groups combined. For example, when considering amoxicillin for the treatment of resistant *S. pneumoniae,* this shows a median PTA of 100% $fT_{>MIC}$ of 1 mg/L, with 95% patients achieving >63% $fT_{>MIC}$.

Protein binding

An important factor contributing to flucloxacillin PK variability is its variable protein binding, which is influenced by many dynamic variables, including body temperature, pH and hypoalbuminaemia. In our study, total flucloxacillin concentrations were measured in plasma, and the simulations assumed protein binding of 95%.[30] However, as a highly protein-bound drug, small absolute differences in protein binding can result in significant relative differences in the pharmacologically active unbound concentration.[46] Marked protein binding variability has been reported in neonates [34.3%–89.7% (mean 74.5%)][47] and adults.[48–50] A recent study in 33 adult ICU patients found that the unbound fraction of flucloxacillin ranged from 7.0% to 71.7%.[48] Previously, Wong *et al.*[49] identified significant differences between measured and predicted concentrations of unbound flucloxacillin in critically ill adults, and identified a non-linear correlation. Variable, concentration-dependent protein binding of flucloxacillin has also been reported in non-critically ill adult patients,[51] while another study demonstrated poor, biased performance of model-based predictions of unbound concentrations.[50] For our interpretation, we have assumed what might be viewed as a worst-case scenario with 95% protein binding (as per the SPC) and it is possible that particularly neonatal participants may have markedly reduced protein binding. This would lead to marked improvements in the PTA curves. Given the literature evidencing extensive interindividual variability in protein binding, this highlights the importance of exploring the feasibility and cost-effectiveness of measuring unbound concentrations in future flucloxacillin PKPD studies. Standardization of protein binding research methods will help to elucidate the clinical and laboratory determinants of variability,[52] since methodological differences also impact on the microbiology and PD.[53]

PKPD variability and individualized dosing

The significant variability in β-lactam PKPD, particularly in critically ill patients, as also demonstrated in this study, has previously been presented as evidence supporting β-lactam therapeutic drug monitoring (TDM).[54,55] Some experts also recommend this approach in paediatrics.[55] However, it remains essential to clarify clinical utility, cost-effectiveness and feasibility in children. A correlation between PTA and clinical outcomes has been identified in some adult research, such as the DALI study,[15] reinforcing interest in β-lactam TDM in adult ICU patients,[56,57] which is now formally advocated.[58] Demonstrating an equivalent correlation in children will prove difficult because of small sample sizes in paediatric/neonatal studies. It can be argued that it is scientifically acceptable to assume that this correlation should also be clinically relevant in children, given the shared underlying microbiological and pharmacological principles of antimicrobial

therapy. The prevalence of ARC in paediatric ICU gives added justification to pursue this further.[37]

PK of oral flucloxacillin

The results in Table 7 represent, to our knowledge, the first published paediatric oral flucloxacillin population PK model. Our estimate for F of 62.7% was similar to the 54.4%±18.8% (in seven elderly patients) reported by Gath *et al.*,[59] and to an earlier study reporting 55.4%±9.2% and 48.%±15.5% (for 24 adults given a 250 and 500 mg capsule, respectively).[60] In contrast, Herngren *et al.*[61] estimated F for nine neonates to be 31.6% (range 21.3% to 45.0%). These studies did not publish the estimated k_a values for flucloxacillin so we could not compare our estimate. However, Gardiner *et al.*[62] estimated k_a for the free concentrations of flucloxacillin to be 0.74 h^{-1} (95% CI 0.15–3.8) and 3.6 h^{-1} (95% CI 0.71–18.2), in the fed and fasting states, respectively, in 12 adult volunteers, and both these 95% CIs overlap with our group estimate of 1.16 h^{-1} (relative standard error, RSE 28.4%). Furthermore, although fasting was associated with increased drug exposure, the PTAs were largely equivalent, suggesting food is unlikely to have a clinically significant effect on flucloxacillin efficacy.[62] Similar studies in children could help to ascertain whether current fasting recommendations can be relaxed.

PK of oral amoxicillin

Our estimate of F for amoxicillin was 58.7% (RSE 15.3%), slightly lower than the 70% reported in the SPC.[28] As oral amoxicillin therapy is potentially of interest for the treatment of suspected neonatal sepsis in resource-limited settings,[63] further neonatal oral PK studies will be valuable. In addition, the PediCAP PK substudy results,[64] investigating amoxicillin and co-amoxiclav PK in pneumonia within a randomized controlled trial, will be of great interest.

Study limitations

Total antibiotic concentrations were measured in plasma; however, measurement of unbound concentrations is recommended for future studies where feasible.[65] It was not possible to measure antibiotic concentrations at other sites (e.g. in CSF), which could be investigated in studies focusing on specific clinical infection syndromes. For the oral PK analysis, the sample sizes were small; larger studies could improve parameter estimate precision.

The study included two β-lactam/BLI combinations but BLI concentrations were not measured. Amoxicillin and co-amoxiclav PK data were merged for the final analysis, since amoxicillin PK is independent of the presence of clavulanic acid.[66] Future paediatric BLI PKPD studies are warranted.[67,68]

Conclusions

We have reported, to our knowledge, the largest prospective combined paediatric penicillin PK study undertaken to date, and the first paediatric oral flucloxacillin PK model. The PTA results demonstrated reassuring performance of BNFC dosing regimens for amoxicillin, benzylpenicillin and piperacillin but the

flucloxacillin PTA was suboptimal. Further research is needed to investigate the clinical relevance of protein binding variability, particularly for flucloxacillin, and the potential clinical utility of β-lactam TDM in children.

NAPPA study consortium members

Tatiana Múnera Huertas, Hana Tabusa, Isabelle Hubbard, Suzie Wright, Jennifer Stuart, Amelia Floresca, Andrew Collinson, Andrew Riordan, Barbara Bromage, Bronagh Howell, Christopher Knight, Debs Heard, Emma Harper, Gita Modgil, Jane Lovatt, Jennie Godwin, Joanne Windrow, Karen Harvey, Kerri McGowan, Kirsty O'Brien, Louise Newbury, Louise Willis, Mark Anthony, Michele Voysey, Michelle Pople, Nasreen Aziz, Nicola Howell, Nicola Thorne, Nigel Klein, Patrick McGowan, Piper Griffin, Prakash Satodia, Rebecca Beckley, Rooba Kauppayamootoo, Sara Davis, Sarah Siner, Sharon Northey, Shaun Larkin, Shelly Segal, Sheula Barlow, Susan Dale, Tamsyn Crane, Tim Scorrer and Zoe Young.

Transparency declarations

All authors declared no competing interests for this work.

Author contributions

C.I.S.B., K.K., M.A.T., A.J., M.S. and J.F.S. were involved in the conception and design of the study. This group, together with K.W., G.T. and M.K., also contributed to study delivery and data acquisition. K.K. analysed the plasma samples (quantifying the antibiotic concentrations). C.I.S.B. coordinated study delivery, led the PK data analysis and interpretation, and drafted the manuscript, with support from D.O.L., M.A.T., A.J., M.S. and J.F.S.. D.O.L. undertook the model-based simulations, with support from C.I.S.B., M.S. and J.F.S. All authors critically reviewed the manuscript and approved the final version.

Supplementary data

Figures S1 to S18, Tables S1 to S13, Supplementary information and Supplementary code are available as Supplementary data at *JAC* Online.

References

1 Fairbrother RW, Daber KS. Oral penicillin. *Lancet* 1954; **266**: 858–60. https://doi.org/10.1016/S0140-6736(54)91421-X

2 Versporten A, Bielicki J, Drapier N *et al.* The worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children. *J Antimicrob Chemother* 2016; **71**: 1106–17. https://doi.org/10.1093/jac/dkv418

3 United Nations Inter-Agency Group for Child Mortality Estimation (UN IGME). Levels and trends in child mortality: UN IGME Report 2022. https://data.unicef.org/resources/levels-and-trends-in-child-mortality/

4 Perin J, Mulick A, Yeung D *et al.* Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the sustainable development goals. *Lancet Child Adolesc Health* 2022; **6**: 106–15. https://doi.org/10.1016/S2352-4642(21)00311-4

5 Fuchs A, Li G, van den Anker JN *et al.* Optimising β -lactam dosing in neonates: a review of pharmacokinetics, drug exposure and pathogens. *Curr Pharm Des* 2017; **23**: 5805–38. https://doi.org/10.2174/1381612823666170925162143

6 Gastine S, Hsia Y, Clements M *et al.* Variation in target attainment of beta-lactam antibiotic dosing between international pediatric formularies. *Clin Pharmacol Ther* 2021; **109**: 958–70. https://doi.org/10.1002/cpt.2180

7 Barker CI, Standing JF, Turner MA *et al.* Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies—and when is enough data enough? *Curr Opin Infect Dis* 2012; **25**: 235–42. https://doi.org/10.1097/QCO.0b013e328353105c

8 Eagle H, Fleischman R, Levy M. "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. *N Engl J Med* 1953; **248**: 481–8. https://doi.org/10.1056/NEJM195303192481201

9 Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clin Infect Dis* 1998; **26**: 1–10; quiz 1-2. https://doi.org/10.1086/516284

10 Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. *Nat Rev Microbiol* 2004; **2**: 289–300. https://doi.org/10.1038/nrmicro862

11 Lodise TP, Lomaestro BM, Drusano GL *et al.* Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy* 2006; **26**: 1320–32. https://doi.org/10.1592/phco.26.9.1320

12 Ja R, Norris R, Paterson DL *et al.* Therapeutic drug monitoring of antimicrobials. *Br J Clin Pharmacol* 2012; **73**: 27–36. https://doi.org/10.1111/j.1365-2125.2011.04080.x

13 Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for *Pseudomonas aeruginosa* infection: clinical implications of an extended-infusion dosing strategy. *Clin Infect Dis* 2007; **44**: 357–63. https://doi.org/10.1086/510590

14 Roberts JA, Lipman J, Blot S *et al.* Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? *Curr Opin Crit Care* 2008; **14**: 390–6. https://doi.org/10.1097/MCC.0b013e3283021b3a

15 Roberts JA, Paul SK, Akova M *et al.* DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? *Clin Infect Dis* 2014; **58**: 1072–83. https://doi.org/10.1093/cid/ciu027

16 Roberts JA, Abdul-Aziz MH, Davis JS *et al.* Continuous versus intermittent β-lactam infusion in severe sepsis: a meta-analysis of individual patient data from randomized trials. *Am J Respir Crit Care Med* 2016; **194**: 681–91. https://doi.org/10.1164/rccm.201601-0024OC

17 Rizk NA, Kanafani ZA, Tabaja HZ *et al.* Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance. *Expert Rev Anti Infect Ther* 2017; **15**: 645–52. https://doi.org/10.1080/14787210.2017.1348894

18 Masich AM, Heavner MS, Gonzales JP *et al.* Pharmacokinetic/pharmacodynamic considerations of beta-lactam antibiotics in adult critically ill patients. *Curr Infect Dis Rep* 2018; **20**: 9. https://doi.org/10.1007/s11908-018-0613-1

19 Harris PA, Taylor R, Thielke R *et al.* Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009; **42**: 377–81. https://doi.org/10.1016/j.jbi.2008.08.010

20 Paediatric Formulary Committee. British National Formulary for Children (BNFC). https://bnfc.nice.org.uk/

21 Barker CI, Sharland M, Turner MA *et al.* Synthesising pragmatic and optimal design: NAPPA - a paediatric penicillin population pharmacokinetic study. *PAGE 23, Alicante, Spain, June 2014.* Abstract 3235. https://www.page-meeting.org/default.asp?abstract=3235

22 Kipper K, Barker CIS, Standing JF *et al.* Development of a novel multi-penicillin assay and assessment of the impact of analyte degradation: lessons for scavenged sampling in antimicrobial pharmacokinetic study design. *Antimicrob Agents Chemother* 2017; **62**: e01540-17.

23 Beal SL. Ways to fit a PK model with some data below the quantification limit. *J Pharmacokinet Pharmacodyn* 2001; **28**: 481–504. https://doi.org/10.1023/A:1012299115260

24 Rhodin MM, Anderson BJ, Peters AM *et al.* Human renal function maturation: a quantitative description using weight and postmenstrual age. *Pediatr Nephrol* 2009; **24**: 67–76. https://doi.org/10.1007/s00467-008-0997-5

25 Kane Z, Gastine S, Obiero C *et al.* IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis. *J Antimicrob Chemother* 2021; **76**: 1855–64. https://doi.org/10.1093/jac/dkab083

26 Ceriotti F, Boyd JC, Klein G *et al.* Reference intervals for serum creatinine concentrations: assessment of available data for global application. *Clin Chem* 2008; **54**: 559–66. https://doi.org/10.1373/clinchem.2007.099648

27 WHO. The WHO Essential Medicines List Antibiotic Book: improving antibiotic AWaReness. 2021. https://www.who.int/publications/m/item/the-who-essential-medicines-list-antibiotic-book-improving-antibiotic-awareness

28 Electronic Medicines Compendium. Amoxicillin 500 mg Capsules. Summary of Product Characteristics. 2017. https://www.medicines.org.uk/emc/product/526/smpc

29 Electronic Medicines Compendium. Benzylpenicillin sodium 600 mg Powder for Injection. Summary of Product Characteristics. 2016. https://www.medicines.org.uk/emc/product/3828/smpc

30 Electronic Medicines Compendium. Flucloxacillin 1 g Powder for Solution for Injection or Infusion. Summary of Product Characteristics. 2018. https://www.medicines.org.uk/emc/product/2239/smpc

31 Electronic Medicines Compendium. Tazocin 4 g / 0.5 g Powder for Solution for Infusion. Summary of Product Characteristics. 2021. https://www.medicines.org.uk/emc/product/1267/smpc

32 EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, valid from 1 January 2022. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf

33 Dien Bard J, Hindler JA, Gold HS *et al.* Rationale for eliminating *Staphylococcus* breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline. *Clin Infect Dis* 2014; **58**: 1287–96. https://doi.org/10.1093/cid/ciu043

34 Germovsek E, Barker CI, Sharland M *et al.* Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful? *Br J Clin Pharmacol* 2017; **83**: 777–90. https://doi.org/10.1111/bcp.13160

35 Germovsek E, Barker CIS, Sharland M *et al.* Pharmacokinetic-pharmacodynamic modeling in pediatric drug development, and the importance of standardized scaling of clearance. *Clin Pharmacokinet* 2019; **58**: 39–52. https://doi.org/10.1007/s40262-018-0659-0

36 Lonsdale DO, Kipper K, Baker EH *et al.* β-Lactam antimicrobial pharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: the ABDose study. *J Antimicrob Chemother* 2020; **75**: 3625–34. https://doi.org/10.1093/jac/dkaa363

37 Rhoney DH, Metzger SA, Nelson NR. Scoping review of augmented renal clearance in critically ill pediatric patients. *Pharmacotherapy* 2021; **41**: 851–63. https://doi.org/10.1002/phar.2617

38 Dhont E, Van Der Heggen T, De Jaeger A *et al.* Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients? *Pediatr Nephrol* 2020; **35**: 25–39. https://doi.org/10.1007/s00467-018-4120-2

39 Kearns GL, Abdel-Rahman SM, Alander SW *et al.* Developmental pharmacology–drug disposition, action, and therapy in infants and children. *N Engl J Med* 2003; **349**: 1157–67. https://doi.org/10.1056/NEJMra035092

40 Ehrnebo M, Agurell S, Jalling B *et al.* Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. *Eur J Clin Pharmacol* 1971; **3**: 189–93. https://doi.org/10.1007/BF00565004

41 Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. *Clin Pharmacokinet* 2013; **52**: 1–8. https://doi.org/10.1007/s40262-012-0018-5

42 Ulldemolins M, Rello J. The relevance of drug volume of distribution in antibiotic dosing. *Curr Pharm Biotechnol* 2011; **12**: 1996–2001. https://doi.org/10.2174/138920111798808365

43 Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient–concepts appraised by the example of antimicrobial agents. *Adv Drug Deliv Rev* 2014; **77**: 3–11. https://doi.org/10.1016/j.addr.2014.07.006

44 Bielicki JA, Cromwell DA, Sharland M. Fifteen-minute consultation: the complexities of empirical antibiotic selection for serious bacterial infections—a practical approach. *Arch Dis Child Educ Pract Ed* 2017; **102**: 117–23. https://doi.org/10.1136/archdischild-2016-310527

45 Ashiru-Oredope D, Sharland M, Charani E *et al.* Improving the quality of antibiotic prescribing in the NHS by developing a new antimicrobial stewardship programme: *Start Smart—Then Focus*. *J Antimicrob Chemother* 2012; **67** Suppl 1: i51–63. https://doi.org/10.1093/jac/dks202

46 Gonzalez D, Schmidt S, Derendorf H. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. *Clin Microbiol Rev* 2013; **26**: 274–88. https://doi.org/10.1128/CMR.00092-12

47 Pullen J, Stolk LM, Degraeuwe PL *et al.* Protein binding of flucloxacillin in neonates. *Ther Drug Monit* 2007; **29**: 279–83. https://doi.org/10.1097/FTD.0b013e318063e30f

48 Wallenburg E, Ter Heine R, de Lange DW *et al.* High unbound flucloxacillin fraction in critically ill patients. *J Antimicrob Chemother* 2021; **76**: 3220–8. https://doi.org/10.1093/jac/dkab314

49 Wong G, Briscoe S, Adnan S *et al.* Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? *Antimicrob Agents Chemother* 2013; **57**: 6165–70. https://doi.org/10.1128/AAC.00951-13

50 Chin PKL, Drennan PG, Gardiner SJ *et al.* Total flucloxacillin plasma concentrations poorly reflect unbound concentrations in hospitalized patients with *Staphylococcus aureus* bacteraemia. *Br J Clin Pharmacol* 2018; **84**: 2311–6. https://doi.org/10.1111/bcp.13673

51 Wilkes S, van Berlo I, Ten Oever J *et al.* Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen. *Int J Antimicrob Agents* 2019; **53**: 310–7. https://doi.org/10.1016/j.ijantimicag.2018.11.018

52 Dalhoff A. Seventy-five years of research on protein binding. *Antimicrob Agents Chemother* 2018; **62**: e01663-17. https://doi.org/10.1128/AAC.01663-17

53 Dalhoff A, Schubert S. The impact of protein binding on antibacterial activities of antibiotics is more than predicted by considering its numerical value alone: impact of preparative and incubation methods on different pharmacodynamic endpoints of β-lactams, macrolides, or fluoroquinolones against Gram-positive and Gram-negative bacteria-Part I. *J Clin Infect Dis Pract* 2016; **4**: 110. https://doi.org/10.4172/2476-213X.1000110

54 Roberts JA, Abdul-Aziz MH, Lipman J *et al.* Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. *Lancet Infect Dis* 2014; **14**: 498–509. https://doi.org/10.1016/S1473-3099(14)70036-2

55 Tu Q, Cotta M, Raman S *et al.* Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations. *Expert Rev Clin Pharmacol* 2021; **14**: 1383–99. https://doi.org/10.1080/17512433.2021.1961578

56 Fratoni AJ, Nicolau DP, Kuti JL. A guide to therapeutic drug monitoring of beta-lactam antibiotics. *Pharmacotherapy* 2021; **41**: 220–33. https://doi.org/10.1002/phar.2505

57 Guilhaumou R, Benaboud S, Bennis Y *et al.* Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French society of pharmacology and therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation—SFAR). *Crit Care* 2019; **23**: 104. https://doi.org/10.1186/s13054-019-2378-9

58 Abdul-Aziz MH, Alffenaar J-WC, Bassetti M *et al.* Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. *Intensive Care Med* 2020; **46**: 1127–53. https://doi.org/10.1007/s00134-020-06050-1

59 Gath J, Charles B, Sampson J *et al*. Pharmacokinetics and bioavailability of flucloxacillin in elderly hospitalized patients. *J Clin Pharmacol* 1995; **35**: 31–6. https://doi.org/10.1002/j.1552-4604.1995.tb04742.x

60 GSK Clinical Studies Register. Bioavailability of Flucloxacillin Capsules (250 and 500 mg). GSK Study ID: 103811. NCT00358371. EudraCT number 2004-004493-81. https://www.gsk-studyregister.com/en/trial-details/? id=103811

61 Herngren L, Ehrnebo M, Broberger U. Pharmacokinetics of free and total flucloxacillin in newborn infants. *Eur J Clin Pharmacol* 1987; **32**: 403–9. https://doi.org/10.1007/BF00543977

62 Gardiner SJ, Drennan PG, Begg R *et al*. In healthy volunteers, taking flucloxacillin with food does not compromise effective plasma concentrations in most circumstances. *PLoS One* 2018; **13**: e0199370. https://doi.org/10.1371/journal.pone.0199370

63 Mir F, Pearce RE, Baig-Ansari N *et al.* Serum amoxicillin levels in young infants (0–59 days) with sepsis treated with oral amoxicillin. *Arch Dis Child* 2020; **105**: 1208–14. https://doi.org/10.1136/archdischild-2019-317342

64 MRC Clinical Trials Unit. PediCAP. https://mrcctu.ucl.ac.uk/studies/all-studies/p/pedicap/.

65 Wong G, Briscoe S, McWhinney B *et al*. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. *J Antimicrob Chemother* 2018; **73**: 3087–94. https://doi.org/10.1093/jac/dky314

66 Adam D, de Visser I, Koeppe P. Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination. *Antimicrob Agents Chemother* 1982; **22**: 353–7. https://doi.org/10.1128/AAC.22.3.353

67 Monogue ML, Nicolau DP. Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target? *Expert Rev Anti Infect Ther* 2019; **17**: 571–82. https://doi.org/10.1080/14787210.2019.1647781

68 Keij FM, Tramper-Stranders GA, Koch BCP *et al.* Pharmacokinetics of clavulanic acid in the pediatric population: a systematic literature review. *Clin Pharmacokinet* 2022; **61**: 637–53. https://doi.org/10.1007/s40262-022-01116-3